09:53 AM EST - ProMetic Life Sciences Inc : Announced today positive interim results from its Open Label Phase 2 clinical trial in patients suffering from idiopathic pulmonary fibrosis. In addition to demonstrating that PBI-4050 is safe and well tolerated in patients suffering from IPF, the objective of this study was to provide early evidence of clinical benefits of PBI-4050 treatment whether used alone or in addition to either nintedanib or pirfenidone. ProMetic Life Sciences Inc
shares T.PLI are trading up $0.07 at $2.76.
